SLDB

Solid Biosciences' stock has increased by 28.9% since the beginning of 2026, trading at $7.27 as of May 9, 2026. On May 7, 2026, Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE clinical trial for SGT-003. The company announced inducement grants of restricted stock units to newly hired employees on May 1, 2026, and March 2, 2026. Solid Biosciences received European Commission Orphan Drug Designation for SGT-003 for Duchenne Muscular Dystrophy around April 2026. In March 2026, the company completed a $240 million private placement, extending its cash runway into the first half of 2028. Positive interim data from the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 was reported in March 2026, showing robust microdystrophin expression and generally favorable safety. The stock price has shown volatility, with a 13% average weekly change over the past three months. Technical analysis indicators in late April and early May 2026 suggested a downward trend, with the stock moving below its 50-day moving average. Shareholder dilution has been identified as a minor risk, with a 27% increase in shares outstanding in the past year.